Common TB drug may fuel superbug resistance, study warns

NCT ID NCT05073926

Ongoing Knowledge-focused Sponsor: Region Skane Source: ClinicalTrials.gov ↗

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study investigates whether taking rifampicin for latent tuberculosis increases the risk of antibiotic resistance in Staphylococcus aureus bacteria that naturally live on the skin. Researchers will compare people treated with rifampicin to those treated with isoniazid, taking swabs before, during, and after treatment to track resistance mutations. They will also check if resistant bacteria can spread to household members.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If it works, this could help doctors choose safer treatments for latent tuberculosis and reduce the spread of antibiotic-resistant bacteria.
What could go wrong: This is an observational study, not a treatment trial. It may not prove cause and effect, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LATENT TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

latent tuberculosis infection staphylococcal infection staphylococcus aureus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LATENT TUBERCULOSIS STAPHYLOCOCCUS AUREUS

Contacts and locations

Show contact details

Locations

Skåne University Hospital

Malmö, 20502, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.